Neuroscience

NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION

TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial...

SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic

Academic research teams of selected projects participate in a translational research program that eliminates barriers that prevent promising discoveries from...

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039,...

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative...

error: Content is protected !!